CLEARSIDE BIOMEDICAL
1.1100
07-November-24 15:59:58
15 minutes delayed
Stocks
+0.0300
+2.78%
Today's range
1.0800 - 1.1300
ISIN
N/A
Source
NASDAQ
-
02 Apr 2024 07:05:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18 Mar 2024 07:05:00 By Nasdaq GlobeNewswire
-
12 Mar 2024 16:05:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK
12 Mar 2024 09:45:16 By NetDania Notify
-
NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK
11 Mar 2024 12:16:48 By NetDania Notify
-
NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK
08 Mar 2024 09:45:23 By NetDania Notify
-
NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK
07 Mar 2024 09:45:03 By NetDania Notify
-
NetDania - New 12 months High: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK
06 Mar 2024 12:23:17 By NetDania Notify
-
29 Feb 2024 07:05:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
07 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
14 Dec 2023 07:05:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
08 Nov 2023 07:05:00 By Nasdaq GlobeNewswire
-
07 Nov 2023 16:20:00 By Nasdaq GlobeNewswire
-
02 Nov 2023 07:05:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
01 Nov 2023 07:05:00 By Nasdaq GlobeNewswire
-
31 Oct 2023 07:05:00 By Nasdaq GlobeNewswire
-
16 Oct 2023 07:05:00 By Nasdaq GlobeNewswire
-
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
03 Oct 2023 16:35:00 By Nasdaq GlobeNewswire